Browse by author
Lookup NU author(s): Professor Deborah Tweddle,
Professor Andrew Pearson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background. This paper reports the toxicity of OPEC/OJEC chemotherapy in stage 4 neuroblastoma patients over 1 year of age. Procedure. Ninety-five patients with stage 4 neuroblastoma received alternating courses of OPEC/ OJEC-vincristine 1.5 mg/m(2) (O), cisplatin 80 mg/m(2) (P), etoposide 200 mg/m(2) (E), cyclophosphamide 600 mg/m(2) (C), and carboplatin 500 mg/m(2) U), every 21 days if there was haematological recovery. Results. Seventy out of ninety-five (74%) patients completed seven or more courses and were evaluable for toxicity. Of these 70 patients, 33% had more than three episodes of fever and sepsis, 35% required more than five blood or platelet transfusions, 36% had grade 2 or more gastrointestinal toxicity and 9% had neurotoxicity. There was a median reduction in GFR of 32 ml/min/1.73 m(2) (-46 to 134) and there was one toxic death. Conclusions. OPEC/OJEC is a well-tolerated therapy for stage 4 neuroblastoma over 1 year of age. Med. Pediatr. Oncol. 36:239-242, 2001. (C) 2001 Wiley-Liss, Inc.
Author(s): Tweddle, D. A., Pinkerton, C. R., Lewis, I. J., Ellershaw, C., Cole, M., Pearson, A. D. J.
Publication type: Article
Publication status: Published
Journal: Medical and Pediatric Oncology
ISSN (print): 0098-1532
Notes: Published in special issue of Medical and Pediatric Oncology: Advances in Neuroblastoma Research: 1998 Conference
Altmetrics provided by Altmetric